Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jilong, Zheng, Zhinan, Lei, Jia, Cao, Yuxin, Li, Qiyun, Zheng, Zhi, Chen, Chuanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321753/
https://www.ncbi.nlm.nih.gov/pubmed/34335707
http://dx.doi.org/10.1155/2021/5589342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321753/
https://www.ncbi.nlm.nih.gov/pubmed/34335707
http://dx.doi.org/10.1155/2021/5589342

Ejemplares similares